$160M deal with Concert helps Vertex maintain dominance in cystic fibrosis
Vertex Pharmaceuticals' move on Monday to acquire a once-a-day cystic fibrosis drug for $160 million from a 69-employee Lexington-based biotech could help the Boston company maintain its "dominant" position in the CF pharmaceuticals market, according to one analyst.
It could also help the smaller biotech, Concert Pharmaceuticals (Nasdaq: CNCE), head off a possible lawsuit in its future.
The deal is part of an effort by Boston-based Vertex (Nasdaq: VRTX) to develop combination-drug regimens that…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Max Stendahl Source Type: news
More News: Biotechnology | Cystic Fibrosis | Health Management | Lawsuits | Legislation | Pharmaceuticals